Fractyl Health (NASDAQ:GUTS – Get Free Report) and Elekta (OTCMKTS:EKTAY – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.
Profitability
This table compares Fractyl Health and Elekta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fractyl Health | N/A | -2,114.58% | -91.50% |
| Elekta | -2.38% | 13.47% | 3.84% |
Earnings and Valuation
This table compares Fractyl Health and Elekta”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fractyl Health | $90,000.00 | 133.13 | -$140.95 million | ($10.56) | -0.09 |
| Elekta | $1.78 billion | 1.29 | -$55.38 million | ($0.12) | -51.78 |
Elekta has higher revenue and earnings than Fractyl Health. Elekta is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Fractyl Health and Elekta, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fractyl Health | 1 | 1 | 3 | 0 | 2.40 |
| Elekta | 0 | 1 | 0 | 0 | 2.00 |
Fractyl Health presently has a consensus price target of $50.25, suggesting a potential upside of 5,461.09%. Given Fractyl Health’s stronger consensus rating and higher probable upside, equities analysts clearly believe Fractyl Health is more favorable than Elekta.
Volatility & Risk
Fractyl Health has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Comparatively, Elekta has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Summary
Fractyl Health beats Elekta on 7 of the 12 factors compared between the two stocks.
About Fractyl Health
Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.
About Elekta
Elekta is a Swedish medical technology company that develops equipment and software for radiation therapy and other treatments used in cancer care and neurosurgery. Founded in 1972 by neurosurgeon Lars Leksell, the company builds on his work in stereotactic radiosurgery. Its offerings include linear accelerators for external-beam radiation therapy, systems for stereotactic radiosurgery and brachytherapy, and software that helps healthcare providers plan and manage treatment. Elekta’s technologies are used by hospitals and clinics to deliver care for cancer and certain neurological conditions.
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
